| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000011776 |
| Receipt No. | R000013617 |
| Official scientific title of the study | A phase I/II study of weekly nab-Paclitaxel/Cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer |
| Date of disclosure of the study information | 2013/09/17 |
| Last modified on | 2018/03/16 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | A phase I/II study of weekly nab-Paclitaxel/Cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer | |
| Title of the study (Brief title) | A phase I/II study of weekly nab-Paclitaxel/Cisplatin in NSCLC | |
| Region |
|
|
| Condition | ||
| Condition | Non-Small-Cell Lung Cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the feasibility and efficacy of nab-paclitaxel and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | objective response rate |
| Key secondary outcomes | progression free survival, overall survival, toxicity |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Level 0; nab-paclitaxel 80mg/m2, day 1,8,15 cisplatin 60mg/m2 day 1 every 4 weeks
Level 1; nab-paclitaxel 80mg/m2, day 1,8,15 cisplatin 75mg/m2 day 1 every 4 weeks Level 2; nab-paclitaxel 100mg/m2, day 1,8,15 cisplatin 75mg/m2 day 1 every 4 weeks |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Histologically or cytologically proven non-squamous non-small cell lung cancer
2)Non-small cell lung cancer with stage IIIB,stage IV (UICC-7) or recurrent disease after surgery 3)EGFR mutation negative, ALK rearrangement negative, other driver oncogenes negative 4)Age: 20- years old 5)ECOG PS 0-1 6)With measurable lesion 7)Adequate organ function 8)Written informed consent |
|||
| Key exclusion criteria | 1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan
2)History of severe drug allergy 3)EGFR mutation positive, ALK rearrangement positive, other driver oncogenes positive 4)History of serious disease condition 5)Symptomatic brain metastasis 6)History of active double cancer 7)History of pregnancy or lactation 8)History of active psychological disease |
|||
| Target sample size | 35 | |||
| Research contact person | |
| Name of lead principal investigator | Miyako Satouchi |
| Organization | Hyogo Cancer Center |
| Division name | Department of Thoracic Oncology |
| Address | 13-70, Kitaoji-cho, Akashi, Hyogo 673-8558, Japan |
| TEL | 078-929-1151 |
| satouchi@hp.pref.hyogo.jp | |
| Public contact | |
| Name of contact person | Yoshihiro Hattori |
| Organization | Hyogo Cancer Center |
| Division name | Department of Thoracic Oncology |
| Address | 13-70, Kitaoji-cho, Akashi, Hyogo 673-8558, Japan |
| TEL | 078-929-1151 |
| Homepage URL | |
| hattori@hp.pref.hyogo.jp | |
| Sponsor | |
| Institute | Hyogo Cancer Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013617 |